FOXC2 and breast cancer: Correspondingly, we clearly show that Dasatinib selectively targets the CD44high/CD24low subpopulation in vitro and inhibits TNBC tumor growth in vivo. In a recent study, PDGFR-β was shown to lie downstream of FOXC2 in BC cells induced to undergo EMT.